Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.
Goyal RK, Cuyun Carter G, Nagar SP, Nash Smyth E, Price GL, Parikh RC, Huang YJ, Li L, Davis KL, Kaye JA. Goyal RK, et al. Among authors: cuyun carter g. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):699-710. doi: 10.1080/14737167.2020.1804871. Epub 2020 Sep 14. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32755262
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL, Sudharshan L, Ryan P, Rajkumar J, Sheffield KM, Nash Smyth E, Morato Guimaraes C, Rybowski S, Cuyun Carter G, Gathirua-Mwangi WG, Huang YJ. Price GL, et al. Among authors: cuyun carter g. Curr Med Res Opin. 2022 Aug;38(8):1319-1331. doi: 10.1080/03007995.2022.2073122. Epub 2022 May 13. Curr Med Res Opin. 2022. PMID: 35535675
Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.
Davie A, Cuyun Carter G, Rider A, Bailey A, Lewis K, Price G, Ostojic H, Ringeisen F, Pivot X. Davie A, et al. Among authors: cuyun carter g. ESMO Open. 2021 Aug;6(4):100226. doi: 10.1016/j.esmoop.2021.100226. Epub 2021 Aug 7. ESMO Open. 2021. PMID: 34371379 Free PMC article.
Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study.
Stephenson JJ, Gable JC, Zincavage R, Price GL, Churchill C, Zhu E, Stenger K, Singhal M, Nepal B, Grabner M, Fisch MJ, Debono D, Geschwender AR, Cuyun Carter G. Stephenson JJ, et al. Among authors: cuyun carter g. Patient Prefer Adherence. 2021 Nov 3;15:2417-2429. doi: 10.2147/PPA.S319239. eCollection 2021. Patient Prefer Adherence. 2021. PMID: 34764640 Free PMC article.
Treatment patterns in patients with advanced gastric cancer in Taiwan.
Cuyun Carter G, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum H, Chen JS. Cuyun Carter G, et al. Asia Pac J Clin Oncol. 2017 Jun;13(3):185-194. doi: 10.1111/ajco.12497. Epub 2016 Apr 25. Asia Pac J Clin Oncol. 2017. PMID: 27108762
Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review.
Cuyún Carter G, Mohanty M, Stenger K, Morato Guimaraes C, Singuru S, Basa P, Singh S, Tongbram V, Kuemmel S, Guarneri V, Tolaney SM. Cuyún Carter G, et al. Cancer Manag Res. 2021 Aug 20;13:6537-6566. doi: 10.2147/CMAR.S300869. eCollection 2021. Cancer Manag Res. 2021. PMID: 34447271 Free PMC article. Review.
21 results